{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:52:00Z","timestamp":1788558720712,"version":"build-2803163510"},"reference-count":31,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,5,3]]},"DOI":"10.1080\/14656566.2026.2669339","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:49:01Z","timestamp":1777967341000},"page":"569-575","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating linaclotide for the treatment of functional constipation in children and adolescents"],"prefix":"10.1080","volume":"27","author":[{"given":"Manuel","family":"Linares","sequence":"first","affiliation":[{"name":"University of Miami","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Saps","sequence":"additional","affiliation":[{"name":"University of Miami","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.02.029"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.2004.tb00890.x"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00771.x"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.015"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01244-9"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13040484"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000266"},{"issue":"4","key":"e_1_3_4_10_1","first-page":"577","article-title":"Evaluation and management of pediatric refractory constipation: recommendations from the NASPGHAN neurogastroenterology and motility committee","volume":"77","author":"Rodriguez L","year":"2023","unstructured":"Rodriguez L, Saps M, Velasco-Ben\u00edtez CA, et al. Evaluation and management of pediatric refractory constipation: recommendations from the NASPGHAN neurogastroenterology and motility committee. J Pediatr Gastroenterol Nutr. 2023;77(4):577\u2013590.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00888-6"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.005"},{"key":"e_1_3_4_13_1","first-page":"515","article-title":"Lubiprostone for the treatment of functional constipation in children","volume":"73","author":"Benninga MA","year":"2021","unstructured":"Benninga MA, Hussain SZ, Sood MR, et al. Lubiprostone for the treatment of functional constipation in children. J Pediatr Gastroenterol Nutr. 2021;73:515\u2013523.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90497-3"},{"key":"e_1_3_4_15_1","first-page":"1329","article-title":"Epithelial receptors and second messengers for bacterial toxins","volume":"124","author":"Giannella RA","year":"2003","unstructured":"Giannella RA, Mann EA. Epithelial receptors and second messengers for bacterial toxins. Gastroenterology. 2003;124:1329\u20131335.","journal-title":"Gastroenterology"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316029"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.09.019"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.199430"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_119"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.01.003"},{"key":"e_1_3_4_21_1","unstructured":"U.S. Food and Drug Administration. Clinical pharmacology review: linaclotide (New drug application [NDA] 202811). Silver Spring (MD): FDA; 2012 [cited 2026 Apr 29]. Available from: https:\/\/www.accessdata.fda.gov"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2024.2383636"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318292f9ea"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2009.01385.x"},{"key":"e_1_3_4_25_1","first-page":"297","article-title":"GUCY2C opposes intestinal tumorigenesis by restricting proliferation and maintaining epithelial integrity","volume":"36","author":"Lin JE","year":"2016","unstructured":"Lin JE, Snook AE, Li P, et al. GUCY2C opposes intestinal tumorigenesis by restricting proliferation and maintaining epithelial integrity. Mol Cell Biol. 2016;36:297\u2013309.","journal-title":"Mol Cell Biol"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0434905100"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58297"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0160"},{"key":"e_1_3_4_29_1","unstructured":"European Medicines Agency. Constella (linaclotide): European public assessment report (EPAR). London: EMA; 2012 [cited 2026 Apr 29]. Available from: https:\/\/www.ema.europa.eu"},{"key":"e_1_3_4_30_1","first-page":"321","article-title":"Safety and efficacy of linaclotide in children aged 7\u201317 years with functional constipation","volume":"76","author":"Di Lorenzo C","year":"2023","unstructured":"Di Lorenzo C, Nurko S, Hyams JS, et al. Safety and efficacy of linaclotide in children aged 7\u201317 years with functional constipation. J Pediatr Gastroenterol Nutr. 2023;76:321\u2013329.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00316-3"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12184"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-04080-5"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2669339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T12:33:51Z","timestamp":1779712431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2669339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5,3]]}},"alternative-id":["10.1080\/14656566.2026.2669339"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2669339","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}